Showing 1 to 10 of 22
| Title | Reference number | Reference number sort | Published | Published date sort | Last updated | Last updated sort |
|---|---|---|---|---|---|---|
| Shared decision making | Reference number:KTT23 | KTT00023 | Published:March 2019 | 20190301 | Last updated:September 2019 | 20190901 |
| Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide | Reference number:KTT24 | KTT00024 | Published:March 2019 | 20190301 | Last updated:September 2019 | 20190901 |
| Chemotherapy dose standardisation | Reference number:KTT22 | KTT00022 | Published:February 2018 | 20180201 | Last updated:September 2019 | 20190901 |
| Multimorbidity and polypharmacy | Reference number:KTT18 | KTT00018 | Published:January 2017 | 20170101 | Last updated:September 2019 | 20190901 |
| Psychotropic medicines in people with learning disabilities whose behaviour challenges | Reference number:KTT19 | KTT00019 | Published:January 2017 | 20170101 | Last updated:September 2019 | 20190901 |
| Safer insulin prescribing | Reference number:KTT20 | KTT00020 | Published:January 2017 | 20170101 | Last updated:September 2019 | 20190901 |
| Medicines optimisation in chronic pain | Reference number:KTT21 | KTT00021 | Published:January 2017 | 20170101 | Last updated:September 2019 | 20190901 |
| Anticoagulants, including direct-acting oral anticoagulants (DOACs) | Reference number:KTT16 | KTT00016 | Published:February 2016 | 20160201 | Last updated:September 2019 | 20190901 |
| Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI | Reference number:KTT17 | KTT00017 | Published:February 2016 | 20160201 | Last updated:September 2019 | 20190901 |
| Type 2 diabetes mellitus: medicines optimisation priorities | Reference number:KTT12 | KTT00012 | Published:January 2015 | 20150101 | Last updated:September 2019 | 20190901 |